Do analysts prefer JATT or SKYE?

Skye Bioscience has a consensus target price of $8.50, suggesting a potential upside of 1,200.29%. Given Skye Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Skye Bioscience is more favorable than JATT Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Skye Bioscience 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has preferable valuation and earnings, JATT or SKYE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio JATT Acquisition N/A N/A $6.85M N/A N/A Skye Bioscience N/A N/A -$55.92M -$1.44 N/A

Is JATT or SKYE more profitable?

JATT Acquisition's return on equity of -49.58% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets JATT Acquisition N/A -49.58% 2.84% Skye Bioscience N/A -217.27% -162.39%

Do analysts rate SKYE or ?

Skye Bioscience currently has a consensus target price of $8.50, indicating a potential upside of 1,200.29%. Given Skye Bioscience's stronger consensus rating and higher probable upside, equities analysts clearly believe Skye Bioscience is more favorable than . Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Skye Bioscience 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, SKYE or ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Skye Bioscience N/A N/A -$55.92M -$1.44 N/A N/A N/A N/A N/A N/A

Is SKYE or more profitable?

's return on equity of 0.00% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Skye Bioscience N/A -217.27% -162.39% N/A N/A N/A

Which has higher valuation & earnings, CGTX or SKYE?

Cognition Therapeutics is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cognition Therapeutics N/A N/A -$23.49M -$0.24 N/A Skye Bioscience N/A N/A -$55.92M -$1.44 N/A

Is CGTX or SKYE more profitable?

Cognition Therapeutics' return on equity of -72.68% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Cognition Therapeutics N/A -72.68% -53.07% Skye Bioscience N/A -217.27% -162.39%

Is SKYE or BTMD more profitable?

biote has a net margin of 8.29% compared to Skye Bioscience's net margin of 0.00%. biote's return on equity of -25.72% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Skye Bioscience N/A -217.27% -162.39% biote 8.29% -25.72% 15.12%

Skye Bioscience (SKYE) Competitors

$0.65 +0.00 (+0.68%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$0.65 -0.01 (-0.87%)

As of 07:08 AM Eastern

Compare

SKYE vs. CRDF, JATT, LONA, CGTX, and BTMD

Should you buy Skye Bioscience stock or one of its competitors? MarketBeat compares Skye Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Skye Bioscience include Cardiff Oncology (CRDF), JATT Acquisition (JATT), Athira Pharma (LONA), Cognition Therapeutics (CGTX), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry.

How does Skye Bioscience compare to Cardiff Oncology?

Skye Bioscience (NASDAQ:SKYE) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Skye Bioscience has a beta of 2.94, suggesting that its share price is 194% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market.

Skye Bioscience has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,527.43%. Cardiff Oncology's return on equity of -95.51% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-217.27%	-162.39%
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%

In the previous week, Cardiff Oncology had 2 more articles in the media than Skye Bioscience. MarketBeat recorded 2 mentions for Cardiff Oncology and 0 mentions for Skye Bioscience. Skye Bioscience's average media sentiment score of 0.00 equaled Cardiff Oncology'saverage media sentiment score.

Company	Overall Sentiment
Skye Bioscience	Neutral
Cardiff Oncology	Neutral

Skye Bioscience currently has a consensus price target of $8.50, suggesting a potential upside of 1,200.29%. Cardiff Oncology has a consensus price target of $7.50, suggesting a potential upside of 794.35%. Given Skye Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Skye Bioscience is more favorable than Cardiff Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 6.2% of Skye Bioscience shares are held by insiders. Comparatively, 8.5% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cardiff Oncology has higher revenue and earnings than Skye Bioscience. Cardiff Oncology is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A
Cardiff Oncology	$590K	97.36	-$45.85M	-$0.67	N/A

Summary

Skye Bioscience and Cardiff Oncology tied by winning 7 of the 14 factors compared between the two stocks.

How does Skye Bioscience compare to JATT Acquisition?

JATT Acquisition (NYSE:JATT) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

48.0% of JATT Acquisition shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by company insiders. Comparatively, 6.2% of Skye Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Skye Bioscience has a consensus target price of $8.50, suggesting a potential upside of 1,200.29%. Given Skye Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Skye Bioscience is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

JATT Acquisition's return on equity of -49.58% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
JATT Acquisition	N/A	-49.58%	2.84%
Skye Bioscience	N/A	-217.27%	-162.39%

In the previous week, JATT Acquisition's average media sentiment score of 0.00 equaled Skye Bioscience'saverage media sentiment score.

Company	Overall Sentiment
JATT Acquisition	Neutral
Skye Bioscience	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A

Summary

JATT Acquisition beats Skye Bioscience on 5 of the 9 factors compared between the two stocks.

How does Skye Bioscience compare to ?

Skye Bioscience (NASDAQ:SKYE) and (:) are related companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

In the previous week, had 925 more articles in the media than Skye Bioscience. MarketBeat recorded 925 mentions for and 0 mentions for Skye Bioscience. Skye Bioscience's average media sentiment score of 0.00 equaled 'saverage media sentiment score.

Company	Overall Sentiment
Skye Bioscience	Neutral
	Neutral

's return on equity of 0.00% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-217.27%	-162.39%
	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A
	N/A	N/A	N/A	N/A	N/A

Skye Bioscience currently has a consensus target price of $8.50, indicating a potential upside of 1,200.29%. Given Skye Bioscience's stronger consensus rating and higher probable upside, equities analysts clearly believe Skye Bioscience is more favorable than .

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

21.1% of Skye Bioscience shares are owned by institutional investors. 6.2% of Skye Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Skye Bioscience beats on 6 of the 9 factors compared between the two stocks.

How does Skye Bioscience compare to Cognition Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Cognition Therapeutics has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Comparatively, Skye Bioscience has a beta of 2.94, indicating that its share price is 194% more volatile than the broader market.

43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are held by institutional investors. 11.1% of Cognition Therapeutics shares are held by insiders. Comparatively, 6.2% of Skye Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Cognition Therapeutics' average media sentiment score of 1.00 beat Skye Bioscience's score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cognition Therapeutics	Positive
Skye Bioscience	Neutral

Cognition Therapeutics' return on equity of -72.68% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-72.68%	-53.07%
Skye Bioscience	N/A	-217.27%	-162.39%

Cognition Therapeutics is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A

Cognition Therapeutics currently has a consensus target price of $3.33, suggesting a potential upside of 251.40%. Skye Bioscience has a consensus target price of $8.50, suggesting a potential upside of 1,200.29%. Given Skye Bioscience's higher probable upside, analysts clearly believe Skye Bioscience is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Cognition Therapeutics beats Skye Bioscience on 8 of the 12 factors compared between the two stocks.

How does Skye Bioscience compare to biote?

Skye Bioscience (NASDAQ:SKYE) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

In the previous week, biote had 1 more articles in the media than Skye Bioscience. MarketBeat recorded 1 mentions for biote and 0 mentions for Skye Bioscience. biote's average media sentiment score of 1.88 beat Skye Bioscience's score of 0.00 indicating that biote is being referred to more favorably in the news media.

Company	Overall Sentiment
Skye Bioscience	Neutral
biote	Very Positive

biote has a net margin of 8.29% compared to Skye Bioscience's net margin of 0.00%. biote's return on equity of -25.72% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-217.27%	-162.39%
biote	8.29%	-25.72%	15.12%

Skye Bioscience has a beta of 2.94, indicating that its stock price is 194% more volatile than the broader market. Comparatively, biote has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market.

21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 6.2% of Skye Bioscience shares are held by company insiders. Comparatively, 32.4% of biote shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

biote has higher revenue and earnings than Skye Bioscience. Skye Bioscience is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A
biote	$192.22M	0.49	$27.05M	$0.44	5.66

Skye Bioscience presently has a consensus target price of $8.50, indicating a potential upside of 1,200.29%. biote has a consensus target price of $2.75, indicating a potential upside of 10.44%. Given Skye Bioscience's higher possible upside, equities research analysts clearly believe Skye Bioscience is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

biote beats Skye Bioscience on 11 of the 14 factors compared between the two stocks.

Get Skye Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SKYE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SKYE vs. The Competition

Export

Metric	Skye Bioscience	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$22.82M	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-0.45	20.49	27.07	23.95
Price / Sales	N/A	300.33	515.05	90.33
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	1.05	7.92	10.62	6.14
Net Income	-$55.92M	$23.81M	$3.60B	$331.74M
7 Day Performance	5.42%	-1.09%	-1.26%	-1.82%
1 Month Performance	-7.58%	2.56%	1.07%	-1.45%
1 Year Performance	-82.47%	42.16%	23.63%	16.32%

Skye Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SKYE Skye Bioscience	1.6043 of 5 stars	$0.65 +0.7%	$8.50 +1,200.3%	-83.2%	$22.82M	N/A	N/A	11
CRDF Cardiff Oncology	3.1979 of 5 stars	$1.31 -3.0%	$7.50 +472.5%	-80.4%	$92.30M	$590K	N/A	20
JATT JATT Acquisition	N/A	$10.76 -6.4%	N/A	+506.8%	$92.29M	N/A	N/A	3	Gap Down
LONA Athira Pharma	2.7703 of 5 stars	$9.44 +8.8%	$15.00 +59.0%	N/A	$91.68M	N/A	N/A	40	Gap Up
CGTX Cognition Therapeutics	3.0947 of 5 stars	$1.01 -1.0%	$3.33 +230.0%	+45.0%	$91.29M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SKYE) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Skye Bioscience (SKYE) Competitors

SKYE vs. CRDF, JATT, LONA, CGTX, and BTMD

How does Skye Bioscience compare to Cardiff Oncology?

Summary

How does Skye Bioscience compare to JATT Acquisition?

Summary

How does Skye Bioscience compare to ?

Summary

How does Skye Bioscience compare to Cognition Therapeutics?

Summary

How does Skye Bioscience compare to biote?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYE vs. The Competition

Skye Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Skye Bioscience (SKYE) Competitors

SKYE vs. CRDF, JATT, LONA, CGTX, and BTMD

How does Skye Bioscience compare to Cardiff Oncology?

Which has more volatility and risk, SKYE or CRDF?

Is SKYE or CRDF more profitable?

Does the media prefer SKYE or CRDF?

Do analysts prefer SKYE or CRDF?

Do insiders and institutionals have more ownership in SKYE or CRDF?

Which has better valuation & earnings, SKYE or CRDF?

Summary

How does Skye Bioscience compare to JATT Acquisition?

Do institutionals & insiders hold more shares of JATT or SKYE?

Do analysts prefer JATT or SKYE?

Is JATT or SKYE more profitable?

Does the media refer more to JATT or SKYE?

Which has preferable valuation and earnings, JATT or SKYE?

Summary

How does Skye Bioscience compare to ?

Does the media prefer SKYE or ?

Is SKYE or more profitable?

Which has higher valuation & earnings, SKYE or ?

Do analysts rate SKYE or ?

Do insiders & institutionals believe in SKYE or ?

Summary

How does Skye Bioscience compare to Cognition Therapeutics?

Which has more volatility and risk, CGTX or SKYE?

Do insiders and institutionals hold more shares of CGTX or SKYE?

Does the media refer more to CGTX or SKYE?

Is CGTX or SKYE more profitable?

Which has higher valuation & earnings, CGTX or SKYE?

Do analysts rate CGTX or SKYE?

Summary

How does Skye Bioscience compare to biote?

Does the media prefer SKYE or BTMD?

Is SKYE or BTMD more profitable?

Which has more volatility and risk, SKYE or BTMD?

Do institutionals and insiders believe in SKYE or BTMD?

Which has better earnings and valuation, SKYE or BTMD?

Do analysts prefer SKYE or BTMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYE vs. The Competition

Skye Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools